Valeant Pharmaceuticals International (VRX) stock prices updated...
 

Valeant Pharmaceuticals International stock price, VRX

Valeant Pharmaceuticals International stock chart:



Valeant Pharmaceuticals International close price: 16.4

Stock price forecast:

UP TO +1.71%
Target: 16.68

Total forecasts: 90
Reached: 51 (56.67%)

Total Win: 49.85 (340.33%)

DaysForecastsReached%Reached points%InvestedUnreached%Total%
90915156.04%49.853.74%623.5432.465.21%82.316.01%
30312683.87%12.762.86%81.200.800.99%13.562.98%
14151066.67%4.942.19%81.200.800.99%5.742.48%
78337.50%1.541.24%81.200.800.99%2.341.83%

Showing 1-10 of 466 items.
Date of ForecastStock PriceTarget PriceForecast Reached Date
2017-02-2116.0416.42017-02-20
2017-02-2016.0416.830000-00-00
2017-02-1916.0417.050000-00-00
2017-02-1816.0417.050000-00-00
2017-02-1716.2217.150000-00-00
2017-02-1616.8617.30000-00-00
2017-02-1515.9816.562017-02-15
2017-02-1414.9715.572017-02-14
2017-02-1315.0415.692017-02-14
2017-02-1215.0415.572017-02-14

Valeant Pharmaceuticals International latest news:


  • 02/21/2017 09:14:20

    UPDATED: EyeGate Pharma surges 49% on news of $4 million Valeant licensing agreement

    EyeGate Pharmaceuticals Inc. shares surged nearly 50% in morning trade Tuesday after an announcement of the company's $4 million licensing agreement with Valeant Pharmaceuticals International Inc. . The deal is for exclusive, global commercial and manufacturing rights for EyeGate's EyeGate II Delivery System, which is an alternative to eye drops and ocular injections, and EGP-437 combination product, which is being developed for post-operative pain and inflammation in patients who've had ocular surgery. The deal consists of cash upfront for EyeGate, and up to $99 million in potential milestone payments and royalties on Valeant's net sales of the product, according to an EyeGate Securities and Exchange Commission filing. Valeant had previously licensed the same product, EGP-437, from EyeGate for uveitis in 2015. EyeGate reported positive results from a early/mid-stage trial in December. Valeant shares lifted 1.3% in Tuesday morning trade. Valeant shares have dropped 11.4% over the last three months, and EyeGate shares have risen 35.3%, compared with a 7.5% rise in the S&P 500 . Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 02/14/2017 15:24:44

    Ackman boosted Chipotle holdings, pared Valeant in 4th quarter

    There were no major surprises in activist hedge-fund manager Bill Ackman's fourth-quarter filing on Tuesday, which showed his Pershing Square Capital boosted its stake in burrito chain Chipotle Mexican Grill and pared its holdings of Valeant Pharmaceuticals . As previously disclosed, Ackman bought more than 2.3 million shares of Chipotle in the fourth quarter, the filing showed, bringing his stake to 2.882 million shares, or 9.96% of the company, as of Dec. 31. Pershing Square and Chipotle reached a settlement in December that gave the fund two seats on restaurant chain's board. Ackman had also disclosed in December that Pershing Square had cut its stake in Valeant by nearly 3.5 million shares to help generate a loss for tax purposes. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 01/10/2017 15:31:07

    BRIEF-Valeant Pharma reiterates its FY 2016 forecast

    * Valeant Pharmaceuticals International Inc - Reiterating its full-year 2016 financial guidance, which was originally communicated in november 2016

  • 01/10/2017 14:55:10

    Williams and Ascena Retail Sink While Illumina, Valeant Jump

    Williams Cos. and Ascena Retail Group take losses in U.S. trading, while Illumina and Valeant Pharmaceuticals International climb

  • 01/09/2017 20:54:51

    Valeant to sell its Dendreon cancer business to China's Sanpower

    Valeant Pharmaceuticals International, Inc. announced Monday night it was selling its Dendreon cancer business to Chinese conglomerate Sanpower Group Co. for $819.9 million in cash. Dandreon's only commercial product is Provenge, a treatment for prostate cancer. "With this sale, we are better aligning our product portfolio with Valeant's new operating strategy by exiting the urological oncology business, which is one of our non-core assets," Valeant CEO Joseph Papa said in a statement. Quebec-based Valeant said it would use the sale proceeds to repay loan debt, and expects the deal to close in the first half of 2017.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • More trends:

    Valero Energy CorporationVLO | Valero Energy Partners LPVLP | ValhiVHI | Validus HoldingsVR | Valley National BancorpVLY | Valley National BancorpVLY.WS | Valley National BancorpVLY^A | Valmont IndustriesVMI | Valspar Corporation (The)VAL | VantivVNTV |